A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)

✍ Scribed by Delbaldo, C.; Serin, D.; Mousseau, M.; Greget, S.; Audhuy, B.; Priou, F.; Berdah, J.F.; Teissier, E.; Laplaige, P.; Zelek, L.; Quinaux, E.; Buyse, M.; Piedbois, P.

• Book ID: 121436174
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 761 KB
• Volume: 50
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2013.09.023